In TROPION-PanTumour01, a phase 1 dose-escalation study involving multiple solid tumor malignancies, Dato-DXd was studied in patients with TNBC and HR+ HER2– breast cancer patients who developed disease relapse from standard treatment or for whom no standard treatment was available. This evidence concerns the gene ERBB2 and breast cancer.